VolitionRx Stock Forecast, Price & News

VolitionRx (NYSEAMERICAN:VNRX) Frequently Asked Questions

Is VolitionRx a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VolitionRx stock.
View analyst ratings for VolitionRx or view top-rated stocks.

When is VolitionRx's next earnings date?

VolitionRx is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for VolitionRx.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) released its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.02. VolitionRx had a negative net margin of 28,471.43% and a negative trailing twelve-month return on equity of 100.42%.
View VolitionRx's earnings history.

What price target have analysts set for VNRX?

2 equities research analysts have issued 12 month price targets for VolitionRx's shares. Their forecasts range from $8.00 to $9.00. On average, they expect VolitionRx's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts' price targets for VolitionRx or view top-rated stocks among Wall Street analysts.

Who are VolitionRx's key executives?

VolitionRx's management team includes the following people:

• Cameron John Reynolds, President, Chief Executive Officer & Director
• Gaetan Michel, Chief Operating Officer
• Terig Hughes, Chief Financial Officer & Treasurer
• Jason Bradley Terrell, Chief Medical Officer & Head-US Operations
• Jacob Vincent Micallef, Chief Scientific Officer

Who are some of VolitionRx's key competitors?

Some companies that are related to VolitionRx include Alpha Teknova (TKNO), MyMD Pharmaceuticals (MYMD), OncoCyte (OCX), Quotient (QTNT), Lucira Health (LHDX), Aspira Women's Health (AWH), Nymox Pharmaceutical (NYMX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), ARCA biopharma (ABIO), StageZero Life Sciences (SZLSF) and StageZero Life Sciences (GNWSF).
View all of VNRX's competitors.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Protalix BioTherapeutics (PLX), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).

What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRx's major shareholders?

VolitionRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lagoda Investment Management L.P. (5.72%), Morgan Stanley (1.09%), BlackRock Inc. (1.01%), Geode Capital Management LLC (0.51%), Renaissance Technologies LLC (0.24%) and Millennium Management LLC (0.12%). Company insiders that own VolitionRx stock include Cameron John Reynolds, Guy Archibald Innes, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes and Salvatore Thomas Butera.
View institutional ownership trends for VolitionRx.

Which institutional investors are selling VolitionRx stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Morgan Stanley, BlackRock Inc., Dimensional Fund Advisors LP, and Citadel Advisors LLC.
View insider buying and selling activity for VolitionRx or view top insider-selling stocks.

Which institutional investors are buying VolitionRx stock?

VNRX stock was bought by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P., Wolverine Trading LLC, Geode Capital Management LLC, and Cowen Prime Advisors LLC. Company insiders that have bought VolitionRx stock in the last two years include Cameron John Reynolds, Guy Archibald Innes, Kim Nguyen, and Salvatore Thomas Butera.
View insider buying and selling activity for VolitionRx or or view top insider-buying stocks.

How do I buy shares of VolitionRx?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.26.

How much money does VolitionRx make?

VolitionRx has a market capitalization of $174.53 million and generates $10 thousand in revenue each year. The medical research company earns $-20.35 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does VolitionRx have?

VolitionRx employs 65 workers across the globe.

What is VolitionRx's official website?

The official website for VolitionRx is www.volitionrx.com.

Where are VolitionRx's headquarters?

VolitionRx is headquartered at 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The medical research company can be reached via phone at (646) 650-1351, via email at [email protected], or via fax at 65 32 8172 5651.